Source: United Kingdom – Executive Government & Departments
The pharmaceutical company Lilly has announced a proof of concept from their BLAZE-1 COVID-19 antibody trial.
Prof Daniel Altmann, Professor of Immunology, Imperial College London, said:
“This is a significant and impressive step forward. From the start of the pandemic, immunologists have worked to produce potent, virus-neutralising monoclonal antibodies as a therapeutic that could be given to block and limit infection. While many of us had thought of this as a possible ‘emergency’ option in an intensive care setting, this study shows that it has value and application in milder cases, reducing the chance of progression to a need for hospitalisation. A joy of this approach is that one can really fine-tune monoclonal antibodies, to the best possible neutralising action against the virus. A downside is that this is hard to roll-out as a widely accessible, affordable option.”
All our previous output on this subject can be seen at this weblink: